Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Lotte Biologics
Deal Size : Undisclosed
Deal Type : Financing
LOTTE BIOLOGICS Announces Investment in PINOT BIO, ADC Platform Development Pioneer
Details : The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeti...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
April 21, 2023
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Lotte Biologics
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : NTX-101
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of NTX-101 in Korean Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 13, 2021
Lead Product(s) : NTX-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NTX-301
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Xennials Therapeutics Australia Pty Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 20, 2021
Lead Product(s) : NTX-301
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Xennials Therapeutics Australia Pty Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FL-118
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Aptamer Group
Deal Size : Undisclosed
Deal Type : Collaboration
Aptamer and PinotBio Collaborate on Drug Conjugates for Targeted Drug Delivery
Details : The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 06, 2021
Lead Product(s) : FL-118
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Aptamer Group
Deal Size : Undisclosed
Deal Type : Collaboration